Answers are grounded in this paper and cite their sources.
The recent failure of semagacestat in two large Phase III studies questions the value of γ-secretase inhibitors in treating Alzheimer's disease. Understanding the reasons of this setback may be important for the future research on effective treatments for this devastating disease.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: